Envoy Medical Files 8-K
Ticker: COCHW · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1840877
Sentiment: neutral
Topics: corporate-filing, financial-reporting
TL;DR
Envoy Medical filed an 8-K on 10/7/25 - standard corporate update.
AI Summary
Envoy Medical, Inc. filed an 8-K on October 7, 2025, reporting on "Other Events" and "Financial Statements and Exhibits." The filing indicates the company's fiscal year ends on December 31st and provides its business address and phone number. It also lists details about its Class Common Stock and Redeemable Warrants.
Why It Matters
This filing provides an update on Envoy Medical's corporate and financial reporting, which is important for investors to track the company's status and any material events.
Risk Assessment
Risk Level: low — This filing appears to be a routine corporate disclosure and does not contain information suggesting immediate high risk.
Key Numbers
- 001-40133 — Commission File Number (Envoy Medical's SEC filing identifier)
- 86-1369123 — IRS Employer Identification No. (Envoy Medical's tax identification number)
Key Players & Entities
- Envoy Medical, Inc. (company) — Registrant
- October 7, 2025 (date) — Date of earliest event reported
- 4875 White Bear Parkway (location) — Business Address
- Anzu Special Acquisition Corp I (company) — Former Company Name
FAQ
What specific 'Other Events' are being reported by Envoy Medical?
The provided text does not detail the specific 'Other Events' beyond listing the item category.
What are the details of Envoy Medical's Class Common Stock?
The filing mentions Class Common Stock with a par value of $0.0001 per share.
What are the terms of Envoy Medical's Redeemable Warrants?
The filing notes Redeemable Warrants, each exercisable for one share of Class Common Stock at an exercise price of $11.50 per share.
When does Envoy Medical's fiscal year end?
Envoy Medical's fiscal year ends on December 31st.
What was Envoy Medical's former company name?
Envoy Medical, Inc. was formerly known as Anzu Special Acquisition Corp I.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-10-07 10:04:00
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
- $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
Filing Documents
- ea0260494-8k_envoy.htm (8-K) — 29KB
- ea026049401ex99-1_envoy.htm (EX-99.1) — 21KB
- 0001213900-25-096845.txt ( ) — 265KB
- coch-20251007.xsd (EX-101.SCH) — 4KB
- coch-20251007_def.xml (EX-101.DEF) — 26KB
- coch-20251007_lab.xml (EX-101.LAB) — 36KB
- coch-20251007_pre.xml (EX-101.PRE) — 25KB
- ea0260494-8k_envoy_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events On October 7, 2025, Envoy Medical, Inc. (the "Company") issued a press release announcing the U.S. Food and Drug Administration's approval of the Company's expansion of its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage. A copy of the press release is attached hereto and incorporated by reference herein as Exhibit 99.1. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Envoy Medical, Inc. Press Release, dated October 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. October 7, 2025 By: /s/ Brent T. Lucas Brent T. Lucas Chief Executive Officer 2